View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 18, 2019

Bayer and Orion report positive data from trial of darolutamide

Bayer and Orion have reported positive results from a Phase III clinical trial (ARAMIS) of darolutamide in patients with non-metastatic castration-resistant prostate cancer.

Bayer and Orion have reported positive results from a Phase III clinical trial (ARAMIS) of darolutamide in patients with non-metastatic castration-resistant prostate cancer.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Darolutamide is designed as a non-steroidal androgen receptor antagonist that binds to and inhibits the receptor function and growth of cancer cells. It is being jointly developed by Bayer and Finnish pharmaceutical company Orion.

Results showed that darolutamide in combination with androgen deprivation therapy (ADT) led to a significant extension in metastasis-free survival (MFS), demonstrating a median of 40.4 months compared to 18.4 months with placebo plus ADT.

Interim analysis of the combination therapy showed a positive trend in overall survival (OD) with a 29% decrease in risk of death.

The findings also revealed a favourable safety profile, with incidence of treatment-emergent adverse events being similar in both investigational and placebo arms.

“With the positive results of ARAMIS trial, we together with Bayer are one step closer of bringing darolutamide to patients and their treating physicians.”

Orion research and development senior vice-president Christer Nordstedt said: “Prostate cancer patients are still in need of treatments that are not only effective but also safe without adverse events that would compromise their quality of life.

“Orion is working hard to bring innovative treatments to cancer patients. With the positive results of ARAMIS trial, we together with Bayer are one step closer of bringing darolutamide to patients and their treating physicians.”

ARAMIS is a double-blind, placebo-controlled trial conducted to assess the safety and efficacy of 600mg darolutamide in a total of 1,509 patients already taking ADT and at high risk of developing metastatic disease.

The randomised, multi-centre trial’s primary endpoint is MFS, measured as the time between randomisation and evidence of metastasis or death.

Secondary endpoints of the trial are OS, time-to-pain progression, initiation of first cytotoxic chemotherapy, first SSE, and characterisation of the safety and tolerability of darolutamide.

The drug is also being evaluated in another Phase III trial called ARASENS, which involves patients suffering from metastatic hormone-sensitive prostate cancer.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena